| Autor: |
Terpos, E. Kostopoulos, I.V. Kastritis, E. Ntanasis-Stathopoulos, I. Migkou, M. Rousakis, P. Argyriou, A.T. Kanellias, N. Fotiou, D. Eleutherakis-Papaiakovou, E. Gavriatopoulou, M. Ziogas, D.C. Papanota, A.-M. Spyropoulou-Vlachou, M. Trougakos, I.P. Tsitsilonis, O.E. Paiva, B. Dimopoulos, M.A. |
| Jazyk: |
angličtina |
| Rok vydání: |
2019 |
| Předmět: |
|
| Popis: |
Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10-5; 17% at 10-6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts' and tumor-associated monocytes/macrophages' predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10-6. © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
